Alnylam stock maintains Buy rating at H.C. Wainwright on strong TTR data

Investing.com - H.C. Wainwright has reiterated its Buy rating and $570.00 price target on Alnylam Pharmaceuticals (NASDAQ:ALNY), a $58.6 billion market cap biotech company that has delivered an impressive 76% return over the past year. According to InvestingPro data, analyst targets for the stock range from $236 to $583, with the current price at $447.

The firm highlighted AMVUTTRA’s Phase 3 HELIOS-B open-label extension data showing durable survival and cardiovascular benefits in TTR amyloidosis with cardiomyopathy (ATTR-CM) through 48 months. The data demonstrated risk reductions of 37% in all-cause mortality or first cardiovascular event across the full population and 42% in the monotherapy group. The company maintains a strong financial position with liquid assets exceeding short-term obligations and operates with a moderate debt level, as highlighted in InvestingPro’s comprehensive analysis.

H.C. Wainwright also noted promising results from the KARDIA-3 Phase 2 trial for zilebesiran in high-risk patients with uncontrolled hypertension, which showed clinically meaningful reductions in systolic blood pressure, particularly in patients on a diuretic at baseline with uncontrolled readings.

Based on these results, Alnylam and collaboration partner Roche announced the initiation of ZENITH, a global Phase 3 cardiovascular outcomes trial, with first patient dosing expected by year-end 2025.

H.C. Wainwright views these updates as extending AMVUTTRA’s differentiation as a first-line therapy in ATTR-CM and increasing visibility on zilebesiran’s potential to deliver a first-in-class, twice-yearly approach to blood pressure control with outcomes upside.

In other recent news, Alnylam Pharmaceuticals has shown strong financial performance with Amvuttra generating approximately $150 million in its first full quarter of sales for ATTR-CM, significantly surpassing both Oppenheimer’s estimate of $10 million and the consensus forecast of $17 million. Oppenheimer responded to this impressive performance by upgrading Alnylam’s stock from Perform to Outperform, setting a price target of $490.00. Additionally, Wolfe Research upgraded Alnylam from Underperform to Peerperform, citing the company’s better-than-expected patient acquisition capabilities.

Alnylam Pharmaceuticals has also received continued support from Truist Securities, which maintained its Buy rating and a $459.00 price target following the presentation of KARDIA3 trial data at the ESC 2025. The firm highlighted the topline data for Cohort A of the Phase 2 KARDIA3 trial and the planned Phase 3 cardiovascular outcomes trial. Piper Sandler reiterated an Overweight rating and a $449.00 price target after Alnylam presented impressive 48-month follow-up data from the Phase III HELIOS-B trial at the European Society of Cardiology Congress.

The data revealed that Amvuttra reduced the risk of all-cause mortality or cardiovascular events by 37% overall and by 42% in patients not receiving tafamidis. These developments underscore Alnylam’s strong position in the pharmaceutical market and its potential for future growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.